Basic Company Data Data as of:  November 22, 2010 Current Price $75.

50
Symbol ALXN ALEXION PHARMACEUTICALS INC H&C Composite Score
Description Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and
Strong Buy
develops proprietary immunoregulatory compounds for the treatment of autoimmune
and cardiovascular diseases.  The Company develops C5 complement inhibitors and
Apogens which are two classes of potential therapeutic compounds designed to
7.2
selectively target specific disease‐causing segments of the immune system.

Sector Health Care
Industry Pharmaceuticals, Biotechnology 0 1 2 3 4 5
Last Report Date 10/21/2010 Technical Score Fundamental Score
Earnings Date 2/11/2011
Fundamentals Technicals
Market Cap.  $6.8 B BETA 0.74 Price $75.50 MACD Trend Up
Price/Earnings 75.50 1Yr. EPS Growth Rate % 125.58% 50‐Day MA $67.29 Stochastics Trend Down
Forward Price/Earnings 31.08 5Yr. Avg. EPS Growth Rate % #N/A N/A 200‐Day MA $56.79 RSI Signal Trend Down
Price/Book 8.45 EPS Growth QoQ 3.45% 50/200 Day MA $10.50 S/T Trend Up
Forward PEG Ratio 1.30 Revenue Growth QoQ 37.94% Volume Pressure 2.06 L/T Trend Up
Return on Equity #N/A N/A Dividend Yield 0.00% Average Daily Volume 937,514 Bull / Bear Bull Trend
LT Debt/Equity 1.51% Cash Flow Per Share 1.33 M‐Score (0 ‐ 100%) 94%
H&C Fundamental Score 4.3 H&C Technical Score 2.9
Ownership Data
Inst. Buy/Sell Ratio 1.82 Management Ownership 1.70%  50 Day Moving Average S/T Support L/T Support
% Change of Insider Holdings 0.79% Short Interest Ratio 2.54  20 Day Moving Average S/T Resistance L/T Resistance

ALEXION PHARMACEUTICALS INC
$78.00
$76.00
$74.00
$72.00
$70.00
$68.00
$66.00
$64.00
$62.00
$60.00
$58.00
$56.00
$54.00
$52.00
$50.00

10.0
Bull Trend Bear Trend
5.0

0.0

‐5.0
2.5
Up / Down Volume Ratio 2.0
1.5
1.0
0.5
0.0
200

100

0
30‐Jul‐10 13‐Aug‐10 27‐Aug‐10 13‐Sep‐10 27‐Sep‐10 11‐Oct‐10 25‐Oct‐10 8‐Nov‐10 22‐Nov‐10
Volume x100,000
Fundamentals
ALEXION PHARMACEUTICALS INC
1
Earnings Per Share 2 Reported Estimate 19
$0.70

$0.60

$0.50

$0.40

$0.30

$0.20

$0.10

$0.00

‐$0.10

‐$0.20

‐$0.30

Total Revenues 1 Ownership EPS & Revenue Growth

Reported Estimate
Investment Advisor 84.32% Quarter EPS Growth Rev. Growth
$250 Hedge Fund Manager 8.65% FQ4 2008 3% # 129%
Pension Fund (ERISA) 2.21% FQ1 2009 191% # 78%
Individual 1.60% FQ2 2009 667% 55%
$200
Mutual Fund Manager 1.56% FQ3 2009 26% 34%
Insurance Company 0.97% FQ4 2009 35% 43%
Corporation 0.37% FQ1 2010 44% 45%
$150
Bank 0.17% FQ2 2010 4% 36%
FQ3 2010 3% 38%
$100 Top Holders and % Outstanding Forward Growth Estimates
FIDELITY MANAGEMENT 14.93% Quarter EPS Growth Rev. Growth
T ROWE PRICE ASSOCIA 6.76% FQ4 2010 116% 39%
$50
COLUMBIA WANGER ASSE 4.74% FQ1 2011 140% 39%
VANGUARD GROUP INC 3.64% FQ2 2011 145% 38%
WELLS CAPITAL MANAGE 3.41% FQ3 2011 108% 30%
$0
JP MORGAN CHASE & CO 3.16%
TURNER INVESTMENT PA 3.00%
WESTFIELD CAPITAL MG 2.63%

Largest Geographic Segmentation of Revenue Product Segmentation of Revenue
Yearly Yearly
Segment Name FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 Segment Name FY 2009 FY 2008 FY 2007 FY 2006 FY 2005
Outside U.S. $226.97 $145.80 $20.19 #N/A N/A #N/A N/A Soliris $386.80 $259.00 $66.38 #N/A N/A #N/A N/A
United States $159.83 $113.20 $51.86 $1.56 $1.06 Contract Research Revenue #N/A N/A $0.10 $5.66 $1.56 $1.06
Worldwide (Contract Research) #N/A N/A $0.10 $5.66 #N/A N/A #N/A N/A